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Review Article
Inflammation as a central mechanism in Alzheimer’s disease
Jefferson W. Kinneya,*, Shane M. Bemillerb, Andrew S. Murtishawa,
Amanda M. Leisganga, Arnold M. Salazara, Bruce T. Lambb
aDepartment of Psychology, University of Nevada Las Vegas, Las Vegas, NV, USA
bStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA
Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is characterized by
cognitive decline and the presence of two core pathologies, amyloid b plaques and neurofibrillary
tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged
as a third core pathology in AD. The sustained activation of the brain’s resident macrophages
(microglia) and other immune cells has been demonstrated to exacerbate both amyloid and tau
pathology and may serve as a link in the pathogenesis of the disorder. In the following review, we
provide an overview of inflammation in AD and a detailed coverage of a number of
microglia-related signaling mechanisms that have been implicated in AD. Additional information
on microglia signaling and a number of cytokines in AD are also reviewed. We also review the
potential connection of risk factors for AD and how theymay be related to inflammatory mechanisms.
 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Overview
Alzheimer’s disease (AD) is a neurodegenerative disorder
that is the most common cause of dementia and is
characterized by the decline in cognitive and function and
neuronal loss. AD currently affects over 5 million
Americans [1] and is expected to become increasingly
prevalent with the rise in life expectancy. It is estimated
that by 2050, 13.8 million Americans will be living with
AD [2]. The financial burden imposed by AD currently
exceeds $230 billion and is expected to reach $1.1 trillion
by 2050 [3]. Given the clinical and financial burden
associated with AD, the identification of novel mechanisms
responsible for pathogenesis, as well as novel therapeutic
targets, is urgently needed.
AD is characterized by two core pathologies, the presence
of b-amyloid (Ab) plaques and neurofibrillary tangles
(NFTs). Ab pathology arises from the improper cleavage
of the amyloid precursor protein (APP) resulting in Ab
monomers that aggregate forming oligomeric Ab and
eventually aggregating into Ab fibrils and plaques [4]. The
function of APP is unknown but is believed to have a role
in cell health and growth [5]. Critical aspects of
understanding the onset of Ab pathology rests on knowing
the mechanisms of the generation of Ab monomers, their
clearance, and their aggregation into oligomeric Ab.
Normal processing of the APP sequence consists of
nonamyloidogenic proteolysis of APP via a-secretase and
l-secretase, producing soluble fragments [6]. When APP
is cleaved by l-secretase and erroneous b-secretase, it leads
to insoluble amyloid b peptides that aggregate in the brain to
form b-amyloid plaques [4,7–17]. The precise role of Ab in
AD pathology remains an open question as Ab plaques may
accumulate up to 10 years before any observable AD
symptoms or diagnosis.
The second core pathology, NFT, arises from the
hyperphosphorylation of tau, a microtubule-associated pro-
tein that stabilizes microtubules [18–27]. Phosphorylation
of tau serves a necessary role in intracellular trafficking to
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remove tau from microtubules, allowing transport, followed
by dephosphorylation to return tau to the microtubule [28].
In AD, tau protein is phosphorylated at multiple sites
resulting in the removal of tau from the microtubule and
causing the collapse of microtubule structures and disruption
in a number of cellular processes ranging from protein
trafficking to overall cellular morphology [29–31]. In
addition, the hyperphosphorylated tau (ptau) aggregates
into paired helical fragments that eventually form
neurofibrillary tangles [20,24,25,32,33]. The accumulation
of ptau tangles and the compromised cellular function
leads to loss of neuronal function, and ultimately
apoptosis [30].
Despite extensive and productive research investigating
the mechanisms responsible for both core pathologies, as
well as approaches aimed at the prevention of Ab plaques
and NFT, there remains no treatment that effectively alters
either pathology in clinical populations [34]. Furthermore,
there exists a considerable gap in the understanding of AD
pathogenesis given these two pathological features. As
stated previously, patients may exhibit Ab plaque pathol-
ogy for up to or greater than a decade before any overt
diagnosis of AD [35,36]. For NFT, the overall tangle
load is correlated with cognitive decline in AD; however,
the appearance of NFT appears to occur before the
inauguration of AD pathology in clinical populations and
preclinical animal models [37–39]. The combination of
the aforementioned gaps in the pathophysiology of AD
suggests that other pathological mechanisms may be
driving both the onset of the disorder, as well as the
progression of the disease.
Over the last 10 years, a third core feature of AD has
emerged that may provide insight into AD pathogenesis,
as well as provide a link between the other two core
pathologies. A number of investigations initially
demonstrated that in addition to Ab plaques and NFT, the
brains of patients with AD exhibited evidence of a sustained
inflammatory response [40–50]. The inflammatory response
has now been observed in multiple studies of postmortem
tissues of AD patient samples [51–57] and is routinely
observed in preclinical model systems of AD.
Acute inflammation in the brain is a well-established
defense against infection, toxins, and injury, but when a
disruption in the equilibrium of anti-inflammatory and
pro-inflammatory signaling occurs, as seen in AD, it results
in chronic inflammation (neuroinflammation) [58–61]. This
chronic neuroinflammation is attributed to activated
microglia cells and the release of numerous cytokines. The
presence of a sustained immune response in the brain is
not exclusive to AD. A number of studies have
demonstrated elevated markers of inflammation in the
brain of patients with Parkinson’s disease (PD) [62–66],
and traumatic brain injury associated with chronic
traumatic encephalopathy (CTE) [67–70], amyotrophic
lateral sclerosis (ALS) [70], and Multiple Sclerosis (MS)
[71] to name a few key examples. It is increasingly recog-
nized that a sustained immune response is a central feature
of neurodegenerative disorders [71–77].
The presence of a sustained inflammatory response in the
brain of patients with AD was, at one point, thought to be
reactive to the neuronal loss occurring in the disorder.
However, substantial body of research has now
demonstrated that a persistent immune response in the brain
is not only associated with neurodegeneration but it also
facilitates and exacerbates both Ab and NFT pathologies.
Furthermore, it has been suggested that the inflammatory
response may provide a link between the initial Ab
pathology and the later development of NFT [78–83]. In
the succeeding sections, we highlight some of the recent
data indicating the role of inflammation in AD, as well as
data indicating inflammation may be a central mechanism
driving Ab pathology and progression.
This review highlights the research supported by the
National Institutes of General Medical Sciences (NIGMS)
through Center for Biomedical Research Excellence
(COBRE) awards that develop the national research
infrastructure.
2. Inflammation in AD
Many studies now point to the involvement of
neuroinflammation playing a fundamental role in the
progression of the neuropathological changes that are
observed in AD. Since the 1980s, there have been reports
of immune-related proteins and cells located within close
proximity to b-amyloid plaques [43,84]. Beginning in the
1990s, several large epidemiological and observational
studies were published indicating that anti-inflammatory
treatments used in diseases, such as rheumatoid arthritis,
showed protective qualities against developing AD,
demonstrating as much as a 50% reduction in the risk for
developing AD in patients who are long-term nonsteroidal
anti-inflammatory drug (NSAID) users [77,85–87]. These
studies lead to studies utilizing animal transgenic AD
models demonstrating that NSAIDs can reduce AD
pathology [88]. Human trials of NSAIDS showed variable
outcomes with no convincing evidence of benefit using the
trial methods of the time [89].
These various epidemiological studies and observational
studies serve as the bedrock of support for neuroinflamma-
tion playing a major role in developing sAD. Unlike other
risk factors and genetic causes of AD, neuroinflammation
is not typically thought to be causal on its own but rather a
result of one or more of the other AD pathologies or risk
factors associated with AD and serves to increase the
severity of the disease by exacerbating b-amyloid and tau
pathologies [90,91].
Brain inflammation appears to have a dual function,
playing a neuroprotective role during an acute-phase
response, but becomes detrimental when a chronic response
is mounted [92]. Chronically activated microglia release a
variety of proinflammatory and toxic products, including
J.W. Kinney et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 575-590576
Downloaded for Anonymous User (n/a) at University of Nevada - Las Vegas from ClinicalKey.com by Elsevier on November 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
reactive oxygen species, nitric oxide, and cytokines. In
deceased patients suffering from recent head trauma, there
is an increase in cerebral Ab deposits 1–3 weeks postinjury,
and it has been shown that elevated levels of interleukin 1
(IL-1) are responsible for the increased APP production
and Ab load [93,94]. In addition, elevated levels of IL-1b
has been shown to increase the production of other
cytokines, including IL-6, which in turn has been shown to
stimulate the activation of CDK5, a kinase known to
hyperphosphorylate tau [95]. The neuroinflammation
observed in AD appears to serve a primary role in
exacerbating Ab burden and tau hyperphosphorylation,
suggesting that this dual role could be a leading link between
these seemingly disparate core AD pathologies. The
mounted immune response via the brain’s resident
macrophage (microglia) is now a central tenant in the
investigation of AD.
2.1. Microglia
Microglia are the resident immune cells within the central
nervous system (CNS) [96]. In a healthy brain, microglia are
in an inactive, “resting” state and are described
morphologically as ramified cells with small somas
[97,98]. In this state, the cell somas are stationary, while
the cell processes extend and retract, surveying their
environment and communicating with neurons and other
glia cells [99–101]. Overall surveillance of the
surrounding neuronal environment is accomplished via a
large number of signaling mechanisms [99,102]. This
includes surveillance of the local neuronal milieu via
numerous receptors for classical neurotransmitters [103],
receptors for numerous cytokines and chemokines
[104–106], and a number of receptors, such as fractalkine
(CX3CR1), that bind ligands constitutively released in
healthy neuronal environments [107]. When microglia
recognize a threat to the CNS, such as invasion, injury, or
disease, it leads to microglial activation, causing a
morphological change resulting in retraction of processes,
enlargement of the cell, and migration [99,108–111].
Transitioning into an activated state may be triggered by
alterations in any number of the aforementioned
mechanisms involved in surveillance.
In AD, it is hypothesized that the primary driver of
activation of microglia is the presence of Ab. Activated
microglia respond to Ab resulting in migration to the
plaques and phagocytosis of Ab [108,112,113]. A number
of investigations have demonstrated that activated
microglia phagocytose Ab [114–117]; however, these
microglia become enlarged and after prolonged periods are
no longer able to process Ab [114,118]. Early in AD
pathogenesis, the mounted immune response results in
clearance of Ab and has been demonstrated to exert
positive effects on AD-related pathologies in animal models’
systems [77,119,120]. However, prolonged activation of the
immune response has been demonstrated to result in an
exacerbation of AD pathology, likely as a result of
sustained activation of microglia in a feed forward loop,
referred to as reactive microgliosis. This results in an
accumulation of Ab and sustained pro-inflammatory
cytokine singling beginning to damage neurons
[118,121,122]. The sustained activation also results in a
decrease in microglia efficiency for binding and
phagocytosing Ab and decreases in Ab degrading enzyme
activity of microglia leading, in turn, to a reduced ability
to break down the Ab plaques [123,124]. However, data
indicate that the microglial capacity for producing
pro-inflammatory cytokines is unaffected [118]. These
data demonstrate a unique feature of pathogenesis in that
overall clearance of Ab becomes compromised while
immune activation continues simultaneously. The continued
release of pro-inflammatory cytokines and associated
neurotoxins from microglia serves to exacerbate the
neuroinflammation and contribute to neurodegeneration,
leading to the activation of yet more microglia.
As the microglia are involved in clearance of Ab, they
release a number of proinflammatory cytokines that recruit
additional microglia to plaques [125–127], resulting in a
characteristic halo of activated microglia surrounding
plaques [112,128]. More recent data indicate that as
microglia become less able to clear Ab, peripheral
macrophages may be recruited to Ab plaque deposition in
an effort to clear Ab [129]. The recruitment of peripheral
macrophages into the brain likely exacerbates the effects
of sustained inflammation and thus AD pathology. Some
of the most compelling data for the importance of
inflammation in AD pathogenesis and the regulation of the
immune response comes from the recent demonstration
that a mutation in the Triggering Receptor Expressed on
Myeloid Cells 2 (TREM2) confers a greater likelihood of
developing AD [129–132]. A rare missense mutation
in TREM2 results in a substantial elevated risk of AD
[133–136].
3. The role of TREM2 in Alzheimer’s disease pathology
Recent identification of a number of genetic variants of
TREM2 has ignited a flurry of research into the mechanistic
contributions of this critical innate immune-regulating
receptor to the pathogenesis of AD and numerous other
neurodegenerative diseases. Original interest in the role of
TREM2 and neurodegeneration was generated in the early
2000s, when associations were identified between TREM2
loss of function mutations and polycystic lipomembranous
osteodysplasia with sclerosing leukoencephalopathy
(PLOSL), or Nasu-Hakola disease [137–139]. This rare
but aggressive neurodegenerative disorder is characterized
by abnormal bone cysts and early-onset dementia with
profound frontal lobe degeneration and is also associated
with mutations in TYROBP, the intracellular signaling
coreceptor for TREM2 [140–142]. In 2012, two
independent studies reported strong associations between
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the R47H variant of TREM2 and late-onset AD [133,136].
The conferral of 2–4.5 fold increased risk of developing
late onset AD (LOAD) in carriers of the R47H allele
positions TREM2 as the strongest associated risk gene
behind only apolipoprotein E-ε4 (ApoE4), and further
implicates innate immunity as a key component to the
pathogenesis of AD [143,144]. In addition to the R47H
variant, the R62H TREM2 mutation has been associated
increased risk of LOAD. Using a variety of approaches
with cell and rodent models along with human patient
tissue and data, great strides have been made to elucidate
the mechanistic contributions of TREM2 in the context
of AD.
Early studies addressing the contributions of TREM2 to
AD pathology utilized the APP/PS1 and 5XFAD mouse
models of Ab pathology along with human AD brain tissues.
Initial characterization of TREM2 in AD revealed
strongly upregulated protein and transcripts on neuritic
plaque-associated macrophages in the brain, but not within
microglia or myeloid cells distal to Ab deposits in amyloid
mice and human AD brain tissues [129,145]. Further
characterization of these plaque-associated cells using flow
cytometry revealed cell surface signatures consistent with
peripheral macrophages, including high expression of
CD45, Ly6c, and CD11 b, although subsequent studies
utilizing parabiosis failed to detect these infiltrates
[129,132,146]. Several studies have identified increased
TREM2 expression in human AD blood, further suggesting
roles for peripheral TREM2 in modifying disease
outcomes [147–149].
Next, the mechanistic roles of TREM2 were explored in
the context of amyloid pathology using APP/PS1 and
5XFAD mice, along with various cellular models. Both hap-
loinsufficiency and complete deletion of Trem2 dramatically
reduces the number of plaque-associated macrophages
throughout all time points of disease in Ab-bearing mice
[129,150]. Interestingly, this decrease in plaque-associated
macrophages reduces hippocampal plaque load at
4-months of age but ultimately exacerbates pathological
outcomes by the 8-month time point [146]. This
phenomenon was accompanied by decreases in
inflammatory cytokines including IL1b, IL6, and TNFa as
well as decreased astrocytosis as measured by GFAP and
S100b later in mid-late stages of pathology. This suggests
that TREM2 alters the inflammatory milieu not only through
macrophage-mediated responses but also through alterations
in astrocyte activation.
Given the profound loss of plaque-associated
macrophages in TREM2-deficient amyloid mice, myeloid
cell survival and proliferation were of interest in these
models. It has been shown that TREM2-deficient mice
have dramatically decreased numbers of proliferating
plaque-associated macrophages as measured by
proliferation markers Ki67, and BrdU in aging APPPS1
and 5XFAD mice [146,151]. In addition, it was shown by
the Colonna lab that TREM2 deficiency results in
increased cleaved caspase-3 activation, resulting in
enhanced myeloid cell death [151]. Utilizing super
resolution microscopy, Yuan et al. further demonstrated
that haploinsufficiency of TREM2 in mice or humans
harboring the R47H mutation results in altered plaque
compaction with much more diffuse and fibrillar plaques
present, and fewer thioflavin S1 dense core plaques [152].
In this situation, more neurotoxic oligomeric and fibrillar
Ab may be present leading to increased neuronal dystrophy
and death. Along with plaque compaction issues, microglia
and macrophages lacking TREM2 have been shown to have
decreased capacity to phagocytose and clear Ab, apoptotic
cells, as well as other proteins and complexes
[131,153,154]. TREM2-deficient myeloid cells also
exhibit increased numbers of autophagy-associated
phagolysosomes reflective of aberrant mTOR activation
resulting in dysregulated metabolic homeostasis within the
context of Ab pathology [155].
More recently, the contributions of TREM2 to tau
pathology have been addressed by the Lamb and Holtzman
groups. Utilizing hTau mice harboring the entire human
tau gene on a complete murine tau knockout background,
Bemiller et al. demonstrated that TREM2 deficiency
worsens cortical soluble and insoluble tau pathology at
6-months of age [156]. This worsening was accompanied
by the presence of morphologically dystrophic microglia
and widespread neuronal stress kinase hyperactivation,
including within ERK-, JNK-, and GSK3b-associated
pathways. The Holtzman group recently reported mitigated
neuroinflammation, astrocytosis, and reduced neurodegen-
eration at advanced ages in the PS19 mouse model of
tauopathy, an aggressive model of tauopathy harboring the
FTD-associated P301S 4R familial tau mutation [157].
Similar to TREM2 signaling in the context of amyloid
pathology, there appear to be disease stage-specific
contributions of TREM2, which normally are protective in
early stages of disease by facilitating clearance of
intracellular and extracellular pathological tau species and
damaged neuronal debris, but transformation to becoming
pathogenic during neurodegenerative phases of disease
where inflammation, astrocytosis, and aberrant synaptic
and neuronal engulfment dominate.
The nuanced roles of TREM2 in promoting neurodegen-
eration can be attributed to three key aspects as currently
understood within the context of AD: (1) regulation of
phagocytic and autophagic processes; (2) myeloid cell
survival and proliferation; and (3) regulation of
inflammation. Recent studies by the Amit, Colonna, and
Schwartz groups highlighted distinct activation patterns for
what have been termed “damage-associated microglia”
[158]. In these studies, the authors demonstrate distinct
myeloid activation patterns, which initially are independent
of TREM2 activation, but later rely on TREM2-dependent
pathways to convert to a neurodegenerative transcriptional
program altering phagocytosis and lipid metabolism. These
studies have further highlighted the disease stage-specific
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responses to pathology along with the incredible heterogene-
ity of cells involved in neurodegenerative processes.
4. Additional microglial receptors
In addition to the TREM2 receptor, a number of other
microglia-specific receptors have been explored in the
investigation of the exaggerated immune response in AD.
4.1. CX3CR1 and AD
To limit the activated role of microglia under resting,
basal conditions in the brain, neurons release a variety of
inhibitory factors, including CX3CL1, a chemokine
frequently referred to as fractalkine [107]. CX3CL1 consists
of a chemokine domain attached to a mucin-rich stalk on the
extracellular domain and is synthesized as a membrane-
anchored protein that may be cleaved into a soluble form
[159,160]. CX3CL1 binds to its obligate receptor,
CX3CR1, on the surface of microglia [161]. Originally
identified on lymphocytes, CX3CR1 is involved with
immune regulation on other tissues, including bone, kidney,
and in the cardiovascular system [162–164]. Despite the
widespread distribution of CX3L1/CX3CR1 signaling
throughout the body, CX3CR1 has been most extensively
studied in microglia [165–167], which have an expression
of CX3CR1 nearly .1000-fold higher when compared
with both peripheral myeloid cells and other CNS cell types,
including both neurons and astrocytes [168,169]. Unlike
other promiscuous chemokines, CX3L1 is the exclusive
ligand for CX3CR1, binding rapidly and with a high
affinity [170]. CX3CL1 is a pleiotropic protein involved in
the abatement of microglia under basal conditions but also
regulates microglial activity by influencing migration and
proliferation in injury conditions [171].
Numerous studies demonstrate that CX3CL1 can
dose-dependently reduce the expression of nitric oxide, IL-
6, and TNFa following stimulation by lipopolysaccharide
and suppress neuronal death induced by microglial
activation [172,173]. CX3CR1-mediated neuronal signaling
to microglia can be disrupted by replacing CX3CR1 with a
green fluorescent protein (GFP) reporter gene that leads to
systemic inflammation and exacerbated microglial
neurotoxicity in a variety of animal models, including PD
ALS [165,174].
However, the role of fractalkine signaling in AD
pathogenesis appears to be complex and is not well
understood. One of the pathogenic hallmarks of AD is
aberrant microglial activation, making the CX3CL1-
CX3CR1 pathway an ideal candidate for investigations of
AD pathophysiology. The effect of CX3CR1 deficiency in
mouse models of AD has been discordant, depending on
the type of models and methods used. For
example, CX3CR1 deletion in a tau transgenic mouse led
to increased tau phosphorylation and aggregation,
increased microglial activation, and exacerbated deficits in
hippocampal-dependent learning [175]. Conversely in
amyloidogenic AD models, deleting CX3CR1-attenuated
neuronal loss and microglial activation with no impact on
amyloidogenesis in 3XTg mice [166] but reduced b-amyloid
deposition in both the APP/PS1 and R1.40 mouse models
[167].
Studies investigating alterations in CX3CL1-CX3CR1
signaling in humans are rare compared with in-vitro and
animal studies; however, the emerging human literature
suggests that the fractalkine pathway may play an important
role in AD pathogenesis. Cortical levels of fractalkine are
reduced in the brains of healthy elderly adults with no
history of dementia or other neurodegenerative disorders
when compared with the brains of healthy, middle-aged
adults, suggesting a potential age effect that may be
associated with altered surveillance by fractalkine receptors
and inflammation [176]. Plasma levels of soluble fractalkine
are elevated in patients with both mild cognitive impairment
(MCI) and AD [177]. In addition, these same researchers
found higher levels of plasma in individuals with
mild-moderate AD than in patients with severe AD and the
highest levels in MCI patients, which is considered a key
turning point from normal aging into AD pathogenesis.
Since inflammation often precedes AD pathology, plasma
levels of CX3CL1 could potentially be a useful systemic
biomarker. Postmortem analyses show modest reductions
of CX3CR1 and markedly lower levels of CX3CL1 in the
hippocampus of AD brains compared with age-matched
nondemented controls [178].
4.2. Alternative receptors on microglia
4.2.1. GABA and GABAB
In the central nervous system, gamma-aminobutyric acid
(GABA) is the primary inhibitory neurotransmitter released
by neurons. Neurons produce GABA by conversion of
glutamate to GABA via glutamate decarboxylases (GADs),
which is released in response to neuronal activity. The
released GABA binds to a fast-acting chloride channel
(GABAA) resulting in rapid hyperpolarization or binding
to a receptor coupled to a metabotropic G-protein coupled
receptor (GABAB) that results in a slow inhibitory
postsynaptic current (IPSC) [179]. As alterations in
GABAergic signaling have been reported in AD
[180–184], and GABA plays a central role in learning and
memory [185,186], there has been interest in its role in
AD. GABA also plays a role in regulation of immune
signaling [186]. Microglia express GABAB receptors [187]
that are in Gi/o subclass of GPCR receptors. Activated
microglia exhibit an upregulation of GABAB
receptors compared with resting microglia [187]. GABA
and GABAB also have anti-inflammatory properties.
Studies have demonstrated that when GABA is released
by astrocytes into the extracellular fluid, it inhibits inflam-
matory responses of activated microglia and astrocytes
J.W. Kinney et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 575-590 579
Downloaded for Anonymous User (n/a) at University of Nevada - Las Vegas from ClinicalKey.com by Elsevier on November 16, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
[186,188,189]. GABA has also been demonstrated to
decrease the release of pro-inflammatory cytokines, TNFa
and IL-6, by activated astrocytes and microglia via GABAB
[186]. In an LPS-induced inflammatory response, activation
of the GABAB receptor reduces the release of IL-12 from
microglia [187]. By utilizing baclofen, a GABAB receptor
agonist, intracellular inflammatory pathways were reduced
by 40–60% [186]. These data clearly indicate GABAB on
microglia serve an anti-inflammatory role [187] suppressing
proinflammatory signaling. In addition, astrocytes
synthesize GABA via monoamine oxidase B (MAOB)
[190], and it has been demonstrated that reactive astrocytes
release large quantities of GABA [186,191] in what is
hypothesized to help regulate microglia function. The
aforementioned data indicate a pathway that is likely
involved in the regulation of microglia function. The
expressed GABAB receptors on microglia likely serve a
role in surveillance of neuronal function as GABA
released from local synapses bind to GABAB on microglia
to suppress pro-inflammatory signaling in a similar fashion
to the fracktalkine ligand and receptor. Furthermore, when
microglia and astrocytes move into a more active state,
GABA release from astrocytes appears to be a mechanism
to regulate and suppress pro-inflammatory signaling in
microglia. If GABAergic tone is compromised in AD, this
suggests the loss of a mechanism to regulate microglia
function. This mechanism is currently the focus of research
in our Center of Biomedical Research Excellence (COBRE)
award, in particular, the investigation of changes in
GABAergic signaling in AD, as well as the role of GABAB
on microglia.
The impact of the TREM2 mutation and other alterations
in microglia receptors that alter microglia activation lead to
the upregulation of a number of pro- and anti-inflammatory
cytokines that regulate the immune response. The evaluation
of these cytokines has become a central part of AD
inflammation investigations.
4.3. Specific cytokine signaling in AD
4.3.1. Pro-inflammatory signaling: TNF-a
TNF-a is one of the more important proinflammatory
cytokines in AD, playing a central role in both initiation
and regulation of the cytokine cascade during a response
to an inflammatory challenge [41,192]. TNF-a increases
vascular endothelial adhesion molecules, allowing
leukocytes and immune cells to migrate into areas under
duress [193].
TNF-a exerts its biological functions by binding to
two main receptors, TNFR1 and TNFR2 [194]. The
overexpression of TNFR1 in mouse hippocampal tissue
was necessary for the activation of NFkB- and Ab-induced
neuronal apoptosis [195]. Conversely, mice lacking
TNFR1 crossed with the APP23 transgenic AD model
exhibit reduced plaque deposition, mitigated hippocampal
microglial activation, and improved performance in
cognitive tasks [196]. High levels of soluble TNFR1 and
TNFR2 can be detected in cerebrospinal fluid (CSF) of
patients diagnosed with MCI who progress to AD on a
6-year follow-up [197].
Increased levels of TNF-a have been reported in both the
brains and plasma of patients with AD [198]. Ab can directly
stimulate microglia production of TNF-a through activation
of the transcription factor NFkB [199]. In addition,
TNF-a can increase Ab burden through the upregulation
of b-secretase production and increased g-secretase activity
[11,200].
4.3.2. Pro-inflammatory signaling: IL-1b
IL-1b has been described as a “master regulator” within
the brain inflammatory cascade due to its integral role in
regulating the expression of other proinflammatory
cytokines, including TNF-a and IL-6, and that disruptions
to IL-1b can delay the onset of neuroinflammation and
neurodegeneration [201].
IL-1 is a proinflammatory cytokine that is upregulated
early in AD development and is considered crucial for
b-amyloid plaque deposition [41]. IL-1b is similarly
elevated in both MCI and AD patients compared with
controls, suggesting that increased IL-1b production begins
early and remains elevated as the disease progresses [202].
Specific IL-1b polymorphisms resulting in higher IL-1b
production are linked to increased AD risk [203]. Increased
levels of IL-1b have been detected in the prefrontal cortex
and hippocampus in brain tissue of patients with AD
[204]. IL-1b-mediated actions are through binding to the
IL-1 receptor, which is expressed throughout the brain but
can be found in greatest concentration in the dentate gyrus
and pyramidal cells in the hippocampus, which are key areas
in the early development of AD pathology [205].
IL-1b regulates the synthesis of APP, increased APP
secretion from glial cells, and amyloidogenic processing of
APP through the activation of protein kinase C and increased
g-secretase activity [11,206]. The ability of IL-1b to
increase Ab burden and plaque deposition creates a
self-sustaining cycle wherein the increase of Ab load results
in further microglia activation and IL-1b production
[207,208].
4.3.3. Pro-inflammatory signaling: IL-6
IL-6 is an important, multifunctional cytokine that
can be considered proinflammatory or anti-inflammatory
depending on the amount and condition in which it was
released [209]. IL-6 is crucial for normal homeostasis of
neuronal tissue, and removal of this signaling pathway leads
to reduced microglial activation, yet overproduction of IL-6
leads to chronic neuroinflammation and neurodegeneration
[210].
Elevated levels of peripheral IL-6 during late midlife
have been reported to effectively predict cognitive decline
in a 10-year longitudinal study [211]. IL-6 is elevated in
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the CSF and serum of AD patients and is considered a
significant contributor to neuroinflammation observed in
LOAD [212,213].
Studies have demonstrated that IL-6 staining in the
hippocampus and cortex is strongly associated with Ab
plaques, which is absent in age-matched controls
[214,215]. Ab has been shown to stimulate the synthesis
and release of IL-6 by glial cells [207]. Activation of IL-6
receptors, which show a regional distribution strongest in
the hippocampus and cortex, has been shown to enhance
APP transcription and expression, as does the IL-6/soluble
IL-6 receptor complex, which can be readily found in serum
and CSF [216]. IL-6 has also been demonstrated to result in
the hyperphosphorylation of several tau epitopes by
increasing CDK5 activity via the CDK5 activator p35,
potentially serving as an important bridge between the
core AD pathologies [95].
4.3.4. Pro-inflammatory signaling: NFkB
The transcription factor NFkB is considered a primary
regulator of inflammatory responses by responding to
proinflammatory stimuli, such as TNF-a or IL-1 [217].
Activated NFkB is predominately found in neurons and glial
cells that are surrounding Ab plaques and is central to
reactive gliosis observed in AD brains [218].
NFkB has been shown to play an important role in
regulating b-site APP cleaving enzyme 1 (BACE1)
transcription, as numerous NFkB binding sites have been
identified near the BACE1 promoter [219]. In addition, Ab
has been shown to stimulate cytokine production through
the NFkB-dependent pathway, resulting in a cyclical loop
of exacerbating pathology [199].
Both in vitro and in vivo studies demonstrate
that utilizing an NFkB inhibitor, such as 6-amino-4(4-
phenoxyphenylethylamino) quinazoline, can reduce
TNF-a-induced BACE1 transcription, resulting in lower
Ab burden [196,220]. Certain NSAIDS, such as
flurbiprofen and indomethacin, have been shown to reduce
NFkB activity, which subsequently results in lower levels
of Ab1–40 and Ab1–42 [221,222].
4.3.5. Anti-inflammatory signaling: IL-10
Interleukin 10 (IL-10) is an anti-inflammatory cytokine
that is found in healthy brain tissue but is upregulated in
patients with AD [223]. There is a correlation between
IL-10 levels and the progression of AD, suggesting that
IL-10 could serve as a biomarker for AD diagnosis and/or
progression. IL-10 is released by both microglia and
astrocytes in response to the increase in pro-inflammatory
cytokines to attempt to maintain homeostasis in the immune
system [224]. IL-10 has been shown to inhibit
pro-inflammatory cytokines, including IL-1a, IL-1b,
TNF-a, IL-6, and the chemokine MCP-1 [223]. These
findings suggest that increases in IL-10 may also be a
possible therapeutic target to manage chronic inflammation,
though clinical trials involving anti-inflammatory agents
have been unsuccessful, and in some studies even
exacerbated the disease [225]. Alternative studies have
supported this claim, by demonstrating that IL-10 can
promote neuroinflammation and cause dysfunction of
microglia. In early AD, microglia perform their role of
activation, migration, and phagocytosis to alleviate the
disease, but as the disease progresses, these functions are
inhibited. A study by Guillot-Sestier et al. (2015) suggests
that this microglia inhibition is related to IL-10.
Il10-deficient APP/PS1 mice (APP/PS11IL-102/2)
showed a reduction of Ab in the cerebrum and an increase
in the amount of activated microglia surrounding the
remaining Ab, suggesting an increase in microglia migration
and phagocytosis [226]. This study also demonstrated that
APP/PS11IL-102/2 mice have reduced synaptic loss and
behavioral impairments in comparison with APP/PS11IL-
101/1 mice. Research also shows that a polymorphism of
IL-10 increases the risk of developing AD in some
populations [227,228].
4.3.6. Anti-inflammatory signaling: TGF-b1
Transforming growth factor-b (TGF-b) is involved in the
regulation of cell growth, cell differentiation, and
immunosuppression. Studies have shown that TGF-b is
elevated in CSF, serum, and brain microvascular endothelial
cells of patients with AD [229,230]. Grammas et al.
demonstrates that this increase of TGF-b in endothelial
cells also provokes the release of pro-inflammatory
cytokines, IL-1b and TGF-a, promoting an inflammatory
response [230]. Within this family of cytokines, the most
abundant isoform is TGF-b1, which is secreted by astrocytes
and is a ligand for receptors found on neurons, astrocytes,
and microglia [231]. TGF-b1 is neuroprotective against
Ab production, deposition, and damage, regulates
neuroinflammation, and inhibits the pathway for the
tau-phosphorylating enzyme, GSK-3b [232]. It is also
responsible for causing an increase in the expression of
Bcl-2 and Bcl-xl, anti-apoptotic proteins. The quantity of
TGF-b1 in plasma has been shown to be decreased in
patients with AD [233,234]. When Ab oligomers are
injected into the hippocampus of mice, decrease in
synaptic protein levels and atrophy of astrocytic processes
occur. However, intracerbroventricular infusion of 10 ng
TGF-b1 30 minutes before an injection of 10 pmol Ab
oligomers resulted in reduced levels of the proteins,
drebrin, PSD-95, and synaptophysin, and strengthening of
astrocytic processes [235]. Also, mice that were
intracerebroventricularly injected with Ab failed to spend
more time with a novel object in a novel object recognition
test, whereas the mice previously injected with TGF-b1 did
not show memory impairments [235]. TGF-b1 deficiency
also causes impairment in the TGF-b1/Smad signaling
pathway. The disruption of this pathway contributes to the
ectopic phosphorylation of Smad2/3, which has been found
in the hippocampal cytoplasm of neurons attached to NFT
and within Ab plaques. There is a negative correlation
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between TGF-b1 mRNA levels and NFT, suggesting that
TGF-b1 deficiency advances tau pathology, causing further
impairment of the TGF-b1/Smad pathway [232]. These
studies demonstrate how disruption of TGF-b1 signaling
contributes to the AD pathogenesis.
The aforementioned studies demonstrate a number of
specific roles for inflammatory mechanisms altered in AD,
as well as a number of mechanisms that are likely related to
AD pathogenesis. Given the very strong relationship between
the missense mutation in TREM2 and the risk for developing
AD, a number of other known risk factors for AD for which
the mechanism underlying the risk is not known have now
been hypothesized to be linked to inflammation.
4.4. Relevance of inflammation and risk factors for AD
A number of risk factors have been identified that confer
greater risk for developing AD. These include age [236],
cardiovascular changes [237], traumatic brain injury
[94,238–240], and metabolic disorders such as diabetes.
Interestingly, each of the aforementioned risk factors also
is associated with an immune response, including in the
brain. This has led to hypotheses that elevated
inflammation and/or inflammatory signaling may be
increasing the risk [241]. As mechanisms are numerous,
we have explained one example below in more detail.
4.4.1. Diabetes mellitus (DM), AD, and inflammation
In addition to the aforementioned pathological hallmarks,
AD is also characterized by abnormal metabolic changes.
Decreased cerebral glucose metabolism is now considered
a distinct characteristic of the AD brain [242–244]. The
association between T2DM and AD is well established,
along with other neurodegenerative diseases, including
vascular dementia and PD [245–247]. One of the first key
studies, the 1999 Rotterdam Study, found that type-2 diabetes
mellitus (T2DM) could double the risk for the development
of AD [248]. Since that seminal Rotterdam Study, numerous
studies have since substantiated this finding that T2DM
nearly doubles the risk for AD [249,250], including that
T2DM serves as a useful predictor for the development of
AD in a 12-year longitudinal study [251,252].
The defining characteristics of T2DM are impairments in
insulin signaling and hyperglycemia [253,254], which
appear to be the main contributing factors increasing the
risk for AD. Impairments in brain insulin signaling as seen
in T2DM has been found to get progressively worse as the
pathology advances in patients with AD, corresponding to
increased levels of amyloid peptides and, in particular,
neuroinflammation [255,256].
A considerable literature has demonstrated that
alterations in insulin levels and insulin receptor resistance
(in particular in T2DM) within the brain impact survival
and function of both neurons and glial cells that are
dependent on intact insulin signaling [257,258]. Insulin is
even neuroprotective by preventing b-amyloid oligomers
from binding within the hippocampus to protect against
AD-related synaptic deterioration [259], and the alterations
in insulin signaling (including insulin receptor resistance)
results in cerebrospinal fluid levels of Ab being higher in
patients with T2DM than nondiabetic controls [260].
Insulin resistance that arises from DM is proposed to
manifest from a prolonged, mild state of inflammation
occurring within peripheral tissue. Adipose tissue has been
shown to recruit macrophage and stimulate the secretion of
numerous proinflammatory cytokines, including TNF-a,
IL-1b, and IL-6, which are then easily distributed throughout
the rest of the body causing systemic inflammation
[261–263]. TNF-a is, in turn, a potent inducer of insulin
resistance occurring within adipose tissue [261,264].
Numerous studies have demonstrated the correlation
between peripheral inflammation and cognitive deficits,
particularly with MCI and AD [265,266]. A meta-analysis
of 40 studies revealed that peripheral cytokines, including
TNF-a, IL-1b, and IL-6, and TGF-b are higher in patients
with AD [267]. Whether the peripheral inflammation is
arising from adiposity or another source, proinflammatory
cytokines can cross the blood-brain barrier, which triggers
brain-specific inflammatory responses [268,269]. Systemic
inflammation is also a primary cause of damage to the
blood-brain barrier, allowing entry of peripheral immune
cells into the brain. Decreased blood-brain barrier integrity
can be observed in rodents that feed on high-fat, high-energy
diets, leading to increased blood-brain barrier permeability,
excessivemicroglial activation, and hippocampal-dependent
learning deficits [270–272]. Compromised blood-brain
barrier integrity can also allow chronic, low-grade systemic
inflammation, as observed in obesity and T2DM, to induce
central inflammation.
Microglia are primed in AD brains to be more susceptible
to secondary inflammatory insults, resulting in an
exacerbated inflammatory response [273]. High-fat chow
can be used in the APP/PS1 mouse model to induce systemic
inflammation that results in profound neuroinflammation
and accelerated AD-pathology, including Ab and tau
hyperphosphorylation, and central insulin resistance [274].
The mechanism of neuronal insulin resistance appears to
be similar with Ab oligomers inducing microglial activation,
which in turn release numerous pro-inflammatory cytokines,
including TNF-a [275]. Although activation of microglia by
Ab is an adaptive physiological response to reducing Ab
burden through phagocytosis, chronic inflammation leads
to exacerbated AD pathology and metabolic abnormalities,
which in turn further exacerbate pathogenesis. These data
are providing evidence for links between molecular
pathways and biochemical abnormalities associated with
inflammatory mechanisms shared between AD and DM.
4.4.2. APOE and inflammation
Apolipoprotein (ApoE) is produced primarily peripher-
ally within the liver and by astrocytes within the CNS.While
the main roles of ApoE involve cholesterol transport,
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regulation of lipid transport, and aid of injury repair within
the brain, ApoE plays a role in glucose metabolism
[276,277]. Owing to the ApoE-ε4 allele representing the
strongest genetic risk factor for late-onset AD (LOAD),
present in nearlyw40% of all patients with AD [278], and
the increasing risk that metabolic disturbances play in
dementia progression, the links between ApoE-ε4, glucose
metabolism, and recently inflammation are important to
understanding the shared underlying mechanisms between
these risk factors.
A recent investigation has highlighted a particularly
important aspect of ApoE risk in AD as it is related to
inflammation. Krasemann et. al., (2017) identified a role
for ApoE signaling in the regulation of microglia phenotype
in response to amyloid b, as well as in other
neurodegenerative disorders [279]. Even more compelling
is that TREM2 signaling appears to mediate a return to
nonpathogenic and reduced phagocytosis of neurons by
microglia. This suggests a completely novel interaction
between one of the major risk factors for developing AD
and microglia function. Additional studies are required to
determine the relationship between ApoE and inflammation,
but this may serve as another example of the central role of
inflammation driving AD pathology. ApoE-ε4 appears to
synergistically combine with other AD risk factors,
including cardiovascular disease, atherosclerosis, and
type-2 diabetes [280]. As each of these other risk factors
includes an evoked immune response in the brain the
possibility exists that inflammation may be the common
thread for increased risk.
5. Summary
The aforementioned sections highlight the central role that
investigations of inflammation in AD has taken in the last
decade and highlight a number of interrelated mechanisms
that may contribute to AD pathogenesis. As the literature
demonstrating the role of inflammation in accelerating core
AD pathologies increases, so should the investigations of
therapeutic approaches targeting the sustained inflammatory
response. In addition, extensive investigations in AD patient
populations as well as pre-clinical model systems needs to
further evaluate microglia signaling cascades and numerous
receptors that have not yet been well characterized. Given
recent hypothesis that extend beyond the findings of
inflammation exacerbating AD pathologies to suggestions
that the inflammatory response evoked by Ab may serve to
seed the onset of tau pathology, the identification of how
the microglia response is regulated and how to modify the
response has become an important topic in potential
treatments of AD.
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RESEARCH IN CONTEXT
1. Systematic review: Inflammation in Alzheimer’s
disease (AD) has emerged as a central pathology
that likely plays a role in onset and progression
of the disease. Numerous investigations have
highlighted that the sustained inflammation in the
brain accelerates other core pathologies, making
inflammatory mechanisms viable targets for
therapeutic development as well. In the below
review, we highlight a number of the inflammatory
mechanisms that have been implicated in AD
pathogenesis. We also highlight links between risk
factors for AD and potential interactions with
inflammatory mechanisms.
2. Interpretation: In the present review we provide
coverage of the interactions of inflammatory
signaling and the progression of AD. We also discuss
a number of possible mechanisms that may account
for connections between altered inflammatory
signaling and the changes observed in AD.
3. Future directions: This review highlights several
emerging mechanisms that may provide a better
understanding of AD pathogenesis as well as may
serve as novel therapeutic targets for treatment
and/or onset of AD.
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